Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellgate begins AMD study
CGC-11047 is a novel polyamine analog that targets the hyper-proliferating blood vessel growth, known as choroidal neovascularization, associated with age-related macular degeneration (AMD). The phase I trial is
CGC-11047 is a novel polyamine analog that targets the hyper-proliferating blood vessel growth, known as choroidal neovascularization, associated with age-related macular degeneration (AMD). The phase I trial is
In addition to recruiting patients in Switzerland, where the phase IIa trial was initiated in May 2006, the study will now also begin recruiting patients at Jean Brown
The study now underway uses the company’s proprietary Mycobacterial Cell Wall-DNA Complex (MCC – trademarked Urocidin) for the treatment of bladder cancer in patients who are unresponsive or
R1507 was selected from a large panel of antibodies and was found to be very good at binding to its target, the insulin-like growth factor-1 receptor (IGF-1R). R1507
The drug, which AstraZeneca has in-licensed from Array BioPharma, inhibits MEK 1/2, an enzyme which regulates cell proliferation and survival. Activation of this pathway has been implicated in
AzaSite Plus, the next product in the AzaSite product franchise, combines azithromycin and dexamethasone in DuraSite which is InSite Vision's drug delivery system for topical ophthalmic indications. The
Novavax scientists created four vaccine candidates to protect against four different subtypes of human and avian influenza, including H5N1, the strain that could possibly set off a pandemic
The drug, known as a aurora kinase inhibitor, works by blocking aurora proteins, which play a key role in cell division and are implicated in the onset and
“The closure of the UK operations is a difficult decision based on a full business analysis,” said Nicholas Teti, Isolagen chairman and CEO. “While we value the hard
Consistent with previously reported results from this study, XL999 showed preliminary evidence of antitumor activity. Cardiac failure and elevated hepatic transaminases were identified as dose-limiting toxicities. In the